News
05-02-2013, 03:34 AM
Selective oestrogen receptor modulators (SERMs: tamoxifen, raloxifene, arzoxifene, and lasofoxifene) significantly reduce the risk of developing the most common type of breast cancer among women at both high and average risk of the disease* both during treatment, and for at least 5 years after stopping, according to the first comprehensive analysis of all SERM prevention trials...
More... (http://www.medicalnewstoday.com/releases/259920.php)
More... (http://www.medicalnewstoday.com/releases/259920.php)